Fresh test for cancer-screening firm Genetron after Nasdaq exit
The onetime star of the U.S. stock market is being privatized with the help of new investors as it adapts to tough challenges in China’s cancer-testing industry Key Takeaways: Genetron…
Recent Articles
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Growing profits, shrinking market share test ZTO’s strategy
2507.HK ZTO.US
